Physician profile
Rendell E Manalo
NPI 1265610950
$1,963.52
in general payments reported to CMS, 2019-2025
18 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $297 · 2021: $195 · 2022: $361 · 2023: $323 · 2024: $383 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $508.21 | 2019-2024 | Lokelma |
| Amgen INC. | $240.75 | 2019-2025 | Tavneos, Parsabiv, Epogen |
| Glaxosmithkline, LLC. | $183.40 | 2022-2025 | Benlysta, Jesduvroq |
| Akebia Therapeutics INC | $154.87 | 2019-2025 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $148.59 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $121.84 | 2020-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $112.25 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $96.05 | 2019-2025 | |
| Baxter Healthcare | $70.00 | 2019 | |
| Calliditas Therapeutics US INC. | $65.28 | 2022-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $51.46 | 2024 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $46.49 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $44.76 | 2021-2023 | Lupkynis |
| Daiichi Sankyo INC. | $35.17 | 2020 | |
| Mallinckrodt Hospital Products INC. | $23.66 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $20.67 | 2022 | |
| Ardelyx, INC. | $20.49 | 2024 | Ibsrela |
| Fresenius USA Marketing, INC. | $19.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rendell Manalo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.